Trials / Unknown
UnknownNCT05255523
Pyrotinib Plus Trastuzumab After First-line TH (P) Treatment With HER-2 Positive Breast Cancer
A Single Arm，Multicenter，Real-world Observational Study of Pyrotinib Plus Trastuzumab After First-line TH (P) Treatment With HER-2 Positive Breast Cancer
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Fujian Medical University Union Hospital · Academic / Other
- Sex
- Female
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the effect of pyrotinib
Detailed description
The purpose of this study is to assess the effect of pyrotinib combined with trastuzumab in the maintenance phase delay/reduction of brain metastases after first-line TH(P) therapy for HER-2-positive advanced breast cancer
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | pyrotinib | After 4-6 cycles of taxane chemotherapeutics combined with trastuzumab±pertuzumab, the assessment result reaches CR or PR, and the subsequent sequential pyrrotinib plus capecitabine±trastuzumab to CNS Progress |
Timeline
- Start date
- 2022-02-20
- Primary completion
- 2023-11-05
- Completion
- 2024-12-20
- First posted
- 2022-02-24
- Last updated
- 2022-02-24
Source: ClinicalTrials.gov record NCT05255523. Inclusion in this directory is not an endorsement.